Peter Morris

Medicine & Life Sciences

1. Child 100%
2. Otitis Media 95%
3. Bronchiectasis 65%
4. Randomized Controlled Trials 55%
5. Suppurative Otitis Media 45%
6. Conjugate Vaccines 45%
7. Northern Territory 42%
8. Haemophilus influenzae 36%
9. Azithromycin 35%
10. Cough 35%
11. Streptococcus pneumoniae 35%
12. Anti-Bacterial Agents 34%
13. Pneumococcal Vaccines 30%
14. Bronchiolitis 29%
15. Haemophilus influenzae glpQ protein 25%
16. Ear 25%
17. Serogroup 23%
18. Placebos 22%
19. 13-valent pneumococcal vaccine 21%
20. Vaccines 19%
21. Middle Ear 19%
22. Lung Diseases 19%
23. Respiratory Tract Infections 16%
24. Otitis Media with Effusion 15%
25. Nasopharynx 15%
26. Health 15%
27. Appointments and Schedules 14%
28. Tympanic Membrane Perforation 14%
29. Vaccination 13%
30. Population 13%
31. PHiD-CV vaccine 13%
32. New Zealand 13%
33. Amoxicillin 12%
34. Nose 12%
35. Ear Diseases 12%
36. Local Anti-Infective Agents 11%
37. Moraxella (Branhamella) catarrhalis 11%
38. Fibrosis 11%
39. Population Groups 11%
40. Vulnerable Populations 10%
41. Pediatrics 10%
42. Confidence Intervals 10%
43. Hearing Loss 9%
44. Microbiology 9%
45. Systematic Reviews 9%
46. Bacteria 9%
47. Pneumonia 9%
48. Minority Groups 9%
49. Therapeutics 9%
50. Polysaccharides 8%